CVRx Inc (CVRX)vsNovartis AG ADR (NVS)
CVRX
CVRx Inc
$4.95
0.00%
HEALTHCARE · Cap: $129.76M
NVS
Novartis AG ADR
$158.83
-0.25%
HEALTHCARE · Cap: $290.96B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 95873% more annual revenue ($56.69B vs $59.07M). NVS leads profitability with a 22.5% profit margin vs -89.1%. NVS earns a higher WallStSmart Score of 51/100 (C-).
CVRX
Avoid29
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+70.9%
Fair Value
$20.90
Current Price
$4.95
$15.95 discount
Margin of Safety
-68.7%
Fair Value
$92.54
Current Price
$158.83
$66.29 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
19.6% revenue growth
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 31.8%
Keeps 23 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -180.9% — below average capital efficiency
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : CVRX
The strongest argument for CVRX centers on Revenue Growth. Revenue growth of 19.6% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 31.8%.
Bear Case : CVRX
The primary concerns for CVRX are EPS Growth, Market Cap, Piotroski F-Score. Debt-to-equity of 2.04 is elevated, increasing financial risk.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
CVRX profiles as a growth stock while NVS is a value play — different risk/reward profiles.
CVRX carries more volatility with a beta of 0.78 — expect wider price swings.
CVRX is growing revenue faster at 19.6% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 29/100), backed by strong 22.5% margins. CVRX offers better value entry with a 70.9% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CVRx Inc
HEALTHCARE · MEDICAL DEVICES · USA
CVRx, Inc. develops implantable technology for the treatment of patients with high blood pressure / hypertension and heart failure.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?